Merck Animal Health to Present Data on Poultry Respiratory Disease Control at World Veterinary Poultry Association Congress (WVPAC)

As Diamond Sponsor, Company Will Host Symposium and Poster Presentations

MADISON, N.J., September 1, 2015 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it will be a Diamond Sponsor of the 19th World Veterinary Poultry Association Congress (WVPAC), taking place in Cape Town, South Africa from September 7-11. As well as presenting data on new vaccines (NOBILIS® Primo QX and INNOVAX® range of products), the company will hold a satellite symposium at the Congress focusing on the control of poultry respiratory disease.

“Merck Animal Health is committed to improving the health and performance of poultry,” said William Vaughn, Global Marketing Director for the company. “Respiratory disease is a significant concern for the poultry industry, so we are pleased to take part in the World Veterinary Poultry Association Congress and provide producers with important information that can help them protect their flocks.”

In addition to more than 10 presentations, Merck Animal Health will highlight important data related to INNOVAX®-ND-ILT, a vector vaccine soon to be available for protecting poultry against infectious laryngotracheitis, as well as Newcastle disease and Marek’s disease:

  • Recombinant vaccine effectiveness against ND problems in layers in highly ND challenged area
    Husam Bakri, Merck Animal Health Scientific Affairs
    Wednesday, September 9, 2015, 14:00-14:15 ; Meeting Room 1.6
  • Double recombinant HVT-based vaccine for simultaneous protection against Newcastle disease, Marek’s disease and infectious laryngotracheitis
    Ian Tarpey, Merck Animal Health, Biology & Discovery
    Wednesday, September 9, 2015, 16:30-16:45; Meeting Room 1.6

At WVPAC, Merck Animal Health will also convene six of the world’s top experts on the subject for a symposium on poultry respiratory disease control, with discussion being driven by live questions from attendees. The symposium will be held at the Cape Town International Convention Centre on September 9 from 17:00-19:00. Congress attendees can contact their local Merck Animal Health representative for more information. Expert panelists at the symposium will include:

  • Dr. Jane Cook , Researcher, Institute for Animal Health, Houghton Laboratory
  • Dr. Richard Currie , President, x-OvO Limited
  • Dr. Sjaak de Wit , Senior Scientist, GD Animal Health Service
  • Dr. Mark Jackwood , Department Head, Poultry Diagnostic and Research Center, University of Georgia
  • Dr. Ian Tarpey , Head of Global Poultry R&D and Global Discovery & Technology, Merck Animal Health
  • Dr. Guillermo Zavala , Founder, Avian Health International

To help more producers improve the performance of their flocks, a limited number of Congress attendees will also be invited to Step Up to Solutions by visiting the top level of Merck Animal Health’s two-story booth, where they can have one-on-one discussions with experts in the poultry industry. Attendees who are interested in attending Step Up to Solutions should contact their local Merck Animal Health sales representative or visit the Merck Animal Health booth #8.

For more information on WVPAC 2015, visit .
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit  or connect with us on LinkedIn and Twitter at @MerckAH.

INNOVAX®is a registered trademark and PROTECTOTYPE ™ is a trademark of Intervet International B.V., a subsidiary of Merck & Co., Inc., Kenilworth, NJ.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( ).